Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship—Response
David J. Gunn, Rebecca A. Cox, Brendan Cronin. Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship—Response. // Clinical and Experimental Ophthalmology. – 2026. – DOI: 10.1111/ceo.70166. – URL: https://onlinelibrary.wiley.com/doi/10.1111/ceo.70166?af=R
David J. Gunn, Rebecca A. Cox, & Brendan Cronin (2026). Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship—Response. Clinical and Experimental Ophthalmology. https://doi.org/10.1111/ceo.70166
David J. Gunn, et al. “Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship—Response.” Clinical and Experimental Ophthalmology, 2026. doi:10.1111/ceo.70166.
@article{Gunn2026,
title = {Femtosecond Laser‐Created Corneal Allogenic Intrastromal Ring Segments for Keratoconus: Technical Promise and the Challenge of Donor Tissue Stewardship—Response},
author = {Gunn, David J. and Cox, Rebecca A. and Cronin, Brendan},
journal = {Clinical and Experimental Ophthalmology},
year = {2026},
doi = {10.1111/ceo.70166},
url = {https://onlinelibrary.wiley.com/doi/10.1111/ceo.70166?af=R}
}
Abstract Purpose To compare the efficacy of intravitreal dexamethasone (DEX) implant‐based regimen versus ranibizumab‐based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Methods Thirty‐seven eyes...
Abstract Foundation models are rapidly emerging as a major development in ophthalmic artificial intelligence, largely because they can achieve strong downstream performance with fewer labelled images than conventional supervised models,...
Abstract Purpose To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods This retrospective...